Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Achondroplasia
NCT06926491Phase 3Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Dec 2024
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infigratinib in achondroplasia (ACH), sponsored by Kyowa Kirin. Primary endpoint: Annualized height velocity at 52 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT06926491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926491.